The history of cannabis and its usage by humans dates back to at least the third millennium BCE in written history, and possibly far further back by. It is unclear when cannabis first became known for its psychoactive properties; some scholars suggest that the ancient Indian drug soma. Editorial Reviews. From Publishers Weekly. Quick?what do Napoleon's troops, Asian cooking, Cannabis: A History - Kindle edition by Martin Booth. Download .
Cannabis of A History
Renewed decriminalization efforts in the s led to the legalization of medicinal marijuana in more than a dozen states, including Alaska, Arizona, California, Colorado, Nevada, Oregon, and Washington. In , however, the U. Supreme Court ruled against the use of marijuana for medical purposes.
Later that year Canada passed legislation easing restrictions on medicinal marijuana. Attorney General Eric Holder issued a new set of guidelines for federal prosecutors in states where the medical use of marijuana was legalized. The policy shift mandated that federal resources were to be focused primarily on prosecuting illegal use and trafficking of marijuana, thereby rendering cases of medical use, in which those individuals in possession of the drug are clearly in compliance with state laws, less prone to excessive legal investigation.
For more information about the medical uses of marijuana, see medical cannabis. In addition to the legalization of medical marijuana, many states in the late 20th and early 21st centuries passed decriminalization laws that imposed penalties other than jail time for possession of a modest amount of marijuana, often imposing a civil fine as punishment instead.
In the U. We welcome suggested improvements to any of our articles. You can make it easier for us to review and, hopefully, publish your contribution by keeping a few points in mind. Your contribution may be further edited by our staff, and its publication is subject to our final approval.
Unfortunately, our editorial approach may not be able to accommodate all contributions. Our editors will review what you've submitted, and if it meets our criteria, we'll add it to the article. Please note that our editors may make some formatting changes or correct spelling or grammatical errors, and may also contact you if any clarifications are needed. The Editors of Encyclopaedia Britannica.
Learn More in these related Britannica articles: Pending formal approval by the governor-general, the legislation paved the way for Canada to join Uruguay as the second country to sanction recreational marijuana use on the national level. Details remained to be worked out, but the federal government was to…. Two major Mafia-like organizations—dubbed drug cartels…. Since the early 21st century, there also has been growth in the production and export of medicinal teas and stevioside, which is extracted from the Stevia rebaudiana plant….
Cannabis drug dependence In drug use: Addiction, habituation, and dependence relationship to hashish In hashish source In cannabis use as aphrodisiac In aphrodisiac legalization in Canada In Canada: Civilian government production in Belize In Belize: Agriculture, forestry, and fishing Colombia In Colombia: The growth of drug trafficking and guerrilla warfare Paraguay In Paraguay: Plant and animal life View More. Articles from Britannica Encyclopedias for elementary and high school students.
Help us improve this article! Contact our editors with your feedback. You may find it helpful to search within the site to see how similar or related subjects are covered. Any text you add should be original, not copied from other sources. At the bottom of the article, feel free to list any sources that support your changes, so that we can fully understand their context. Internet URLs are the best. Thank You for Your Contribution! With regard to the management of neurological disorders, including epilepsy and MS, a Cochrane review of four clinical trials that included 48 epileptic patients using CBD as an adjunct treatment to other antiepileptic medications concluded that there were no serious adverse effects associated with CBD use but that no reliable conclusions on the efficacy and safety of the therapy can be drawn from this limited evidence.
In older patients, medical cannabinoids have shown no efficacy on dyskinesia, breathlessness, and chemotherapy-induced nausea and vomiting. Some evidence has shown that THC might be useful in treatment of anorexia and behavioral symptoms in patients with dementia. The most common adverse events reported during cannabinoid treatment in older adults were sedation-like symptoms. Despite limited clinical evidence, a number of medical conditions and associated symptoms have been approved by state legislatures as qualifying conditions for medicinal cannabis use.
Table 1 contains a summary of medicinal cannabis indications by state, including select disease states and qualifying debilitating medical conditions or symptoms. A total of 28 states, the District of Columbia, Guam, and Puerto Rico now allow comprehensive public medical marijuana and cannabis programs. Medicinal Cannabis Indications for Use by State 10 , 60 , Table adapted with permission from the Marijuana Policy Project; 60 table is not all-encompassing and other medical conditions for use may exist.
The reader should refer to individual state laws regarding medicinal cannabis for specific details of approved conditions for use. In addition, states may permit the addition of approved indications; list is subject to change.
Some of the most common policy questions regarding medical cannabis now include how to regulate its recommendation and indications for use; dispensing, including quality and standardization of cultivars or strains, labeling, packaging, and role of the pharmacist or health care professional in education or administration; and registration of approved patients and providers.
The regulation of cannabis therapy is complex and unique; possession, cultivation, and distribution of this substance, regardless of purpose, remain illegal at the federal level, while states that permit medicinal cannabis use have established individual laws and restrictions on the sale of cannabis for medical purposes.
In a U. Department of Justice memorandum to all U. Cole noted that despite the enactment of state laws authorizing marijuana production and sale having a regulatory structure that is counter to the usual joint efforts of federal authorities working together with local jurisdictions, prosecution of individuals cultivating and distributing marijuana to seriously ill individuals for medicinal purpose has not been identified as a federal priority. There are, however, other regulatory implications to consider based on the federal restriction of cannabis.
Medical cannabis expenses are not reimbursable through government medical assistance programs or private health insurers. As previously described, the Schedule I listing of cannabis according to federal law and DEA regulations has led to difficulties in access for research purposes; nonpractitioner researchers can register with the DEA more easily to study substances in Schedules II—V compared with Schedule I substances.
For example, the Center for Medicinal Cannabis Research at the University of California—San Diego had access to funding, marijuana at different THC levels, and approval for a number of clinical research trials, and yet failed to recruit an adequate number of patients to conduct five major trials, which were subsequently canceled.
The limited availability of clinical research to support or refute therapeutic claims and indications for use of cannabis for medicinal purposes has frequently left both state legislative authorities and clinicians to rely on anecdotal evidence, which has not been subjected to the same rigors of peer review and scrutiny as well-conducted, randomized trials, to validate the safety and efficacy of medicinal cannabis therapy.
Furthermore, although individual single-entity pharmaceutical medications, such as dronabinol, have been isolated, evaluated, and approved for use by the FDA, a plant cannot be patented and mass produced by a corporate entity. The Schedule I designation of cannabis causes hospitals and other care settings that receive federal funding, either through Medicare reimbursement or other federal grants or programs, to pause to consider the potential for loss of these funds should the federal government intercede and take action if patients are permitted to use this therapy on campus.
Similarly, licensed practitioners registered to certify patients for state medicinal cannabis programs may have comparable concerns regarding jeopardizing their federal DEA registrations and ability to prescribe other controlled substances as well as jeopardizing Medicare reimbursements.
Attorney General Eric Holder recommended that enforcement of federal marijuana laws not be a priority in states that have enacted medicinal cannabis programs and are enforcing the rules and regulations of such a program; despite this, concerns persist. The argument for or against the use of medicinal cannabis in the acute care setting encompasses both legal and ethical considerations, with the argument against use perhaps seeming obvious on its surface.
States adopting medical cannabis laws may advise patients to utilize the therapy only in their own residence and not to transport the substances unless absolutely necessary. Canada has adopted national regulations to control and standardize dried cannabis for medical use. The argument can be made that an herb- or plant-based entity cannot be identified by pharmacy personnel as is commonly done for traditional medicines, although medicinal cannabis dispensed through state programs must be labeled in accordance with state laws.
Dispensing and storage concerns, including an evaluation of where and how this product should be stored e. Inpatient use of medicinal cannabis also carries implications for nursing and medical staff members. The therapy cannot be prescribed, and states may require physicians authorizing patient use to be registered with local programs.
Despite the complexities in the logistics of continuing medicinal cannabis in the acute care setting, proponents of palliative care and continuity of care argue that prohibiting medicinal cannabis use disrupts treatment of chronic and debilitating medical conditions. Patients have been denied this therapy during acute care hospitalizations for reasons stated above. Legislation in Minnesota, as one example, has been amended to permit hospitals as facilities that can dispense and control cannabis use; similar legislative actions protecting nurses from criminal, civil, or disciplinary action when administering medical cannabis to qualified patients have been enacted in Connecticut and Maine.
Despite lingering controversy, use of botanical cannabis for medicinal purposes represents the revival of a plant with historical significance reemerging in present day health care. Legislation governing use of medicinal cannabis continues to evolve rapidly, necessitating that pharmacists and other clinicians keep abreast of new or changing state regulations and institutional implications. Ultimately, as the medicinal cannabis landscape continues to evolve, hospitals, acute care facilities, clinics, hospices, and long-term care centers need to consider the implications, address logistical concerns, and explore the feasibility of permitting patient access to this treatment.
Whether national policy—particularly with a new presidential administration—will offer some clarity or further complicate regulation of this treatment remains to be seen. The authors report no commercial or financial interests in regard to this article.
National Center for Biotechnology Information , U. Journal List P T v. Author information Copyright and License information Disclaimer. This article has been cited by other articles in PMC. Open in a separate window. Access to marijuana through home cultivation, dispensaries, or some other system that is likely to be implemented;.
Allows either smoking or vaporization of some kind of marijuana products, plant material, or extract. Schedules of controlled substances. Department of Justice; Management of substance abuse: Behavioral health trends in the United States: Office of National Drug Control Policy.
Answers to frequently asked questions about marijuana. Medicinal use of marijuana—polling results. N Engl J Med. Kondrad E, Reid A. J Am Board Fam Med. Moeller KE, Woods B. Am J Pharm Educ. National Conference of State Legislatures. State medical marijuana laws. Food and Drug Administration. FDA work on medical products containing marijuana.
Food and Drug Administration; Mar, A Complete Guide to Cannabis. Park Street Press; Early medical use of cannabis. The Marihuana Tax Act of The advisability and feasibility of developing USP standards for medical cannabis.
Pharmacopeial Convention; [Accessed August 5, ]. Encyclopedia of Drug Policy. State marijuana laws in map. Comparing cannabis with tobacco—again. National Institute on Drug Abuse. Should marijuana be a medical option? MacDonald K, Pappas K. A multi-facet therapeutic target. Care and feeding of the endocannabinoid system: International Union of Basic and Clinical Pharmacology.
Cannabinoid receptors and their ligands: Current status and prospects for cannabidiol preparations as new therapeutic agents. Zhornitsky S, Potvin S. Cannabidiol in humans—the quest for therapeutic targets.
Pharmaceuticals Basel ; 5: Is legalization impacting the way people use cannabis? Int J Drug Policy. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol, and cannabinol. Controlled cannabis vaporizer administration: Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Pharmacokinetics and pharmacodynamics of cannabinoids. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: Sativex oral mucosal spray.
Marinol dronabinol capsules USP prescribing information. Adverse health effects of marijuana use. Association between cannabis and psychosis: Keep off the grass? Cannabis, cognition, and addiction. Marijuana and lung diseases. Curr Opin Pulm Med. Cannabis use and risk of psychiatric disorders: Early cannabis use and estimated risk of later onset of depression spells: Cannabis, ischemic stroke, and transient ischemic attack: Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana: Acute and long-term effects of cannabis use: Examining the roles of cannabinoids in pain and other therapeutic indications: Adverse effects of medical cannabinoids:
Why the U.S. Made Marijuana Illegal
Buy Cannabis: A History on bestallcialis.top ✓ FREE SHIPPING on qualified orders. You may be getting high on dividends from the latest marijuana stock TheStreet gives you a comprehensive history of marijuana, and what's. The cannabis plant has had a long—really long!—history. The plant, and the way it is used, has changed a lot over the centuries.